Enliven Therapeutics's total assets for Q1 2026 were $464.85M, a decrease of -2.38% from the previous quarter. ELVN total liabilities were $11.49M for the fiscal quarter, a -31.12% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.